Zobrazeno 1 - 10
of 175
pro vyhledávání: '"James R Powell"'
Autor:
Paul E. Drawz, Nayanjot Kaur Rai, Kristin Macfarlane Lenoir, Maritza Suarez, James R. Powell, Dominic S. Raj, Srinivasan Beddhu, Anil K. Agarwal, Sandeep Soman, Paul K. Whelton, James Lash, Frederic F. Rahbari-Oskoui, Mirela Dobre, Mark A. Parkulo, Michael V. Rocco, Andrew McWilliams, Jamie P. Dwyer, George Thomas, Mahboob Rahman, Suzanne Oparil, Edward Horwitz, Nicholas M. Pajewski, Areef Ishani
Publikováno v:
Kidney360
Adjudication of inpatient AKI in the Systolic Blood Pressure Intervention Trial (SPRINT) was based on billing codes and admission and discharge notes. The purpose of this study was to evaluate the effect of intensive versus standard BP control on cre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5effe94ab5a3e896a38cb7bff5b73831
https://doi.org/10.34067/kid.0001572022
https://doi.org/10.34067/kid.0001572022
Publikováno v:
Primary Care Diabetes. 16:471-473
Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender difference, those differences exist. On restricting the CVOTs results to women with increased CV r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36310f0cae2fd052454f69e419093195
https://doi.org/10.1016/j.pcd.2022.03.012
https://doi.org/10.1016/j.pcd.2022.03.012
Publikováno v:
Entropy, Vol 22, Iss 7, p 795 (2020)
The cosmological singularity of infinite density, temperature, and spacetime curvature is the classical limit of Friedmann’s general relativity solutions extrapolated to the origin of the standard model of cosmology. Jacob Bekenstein suggests that
Externí odkaz:
https://doaj.org/article/a356ae34965740f7b1232ea7c35d1892
Autor:
BASEM M. MISHRIKY, DOYLE M. CUMMINGS, YUANYUAN FU, JACQUIE HALLADAY, WILLIAM S. JONES, ANDREA BOAN, SARA JONES BERKELEY, SHIVAJIRAO P. PATIL, JAMES R. POWELL, ALYSSA ADAMS, WILLIAM IRISH
Publikováno v:
Diabetes. 71
While African Americans (AA) were underrepresented in the SGLT2i CVOT, the results from those trials were generalized to all, regardless of race. Our goal was to evaluate the risk of heart failure hospitalization (hHF) among AA vs. White (Wh) vs. His
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15460b1e82c0ca0b6e7a7bc83c68895c
https://doi.org/10.2337/db22-20-lb
https://doi.org/10.2337/db22-20-lb
Autor:
Chi D. Chu, Kristin M. Lenoir, Nayanjot Kaur Rai, Sandeep Soman, Jamie P. Dwyer, Michael V. Rocco, Anil K. Agarwal, Srinivasan Beddhu, James R. Powell, Maritza M. Suarez, James P. Lash, Andrew McWilliams, Paul K. Whelton, Paul E. Drawz, Nicholas M. Pajewski, Areef Ishani, Delphine S. Tuot
Publikováno v:
Contemporary Clinical Trials. 128:107172
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2b28f19eeb3c986d8c9b851f96a8eb0
https://doi.org/10.1016/j.cct.2023.107172
https://doi.org/10.1016/j.cct.2023.107172
Publikováno v:
Primary care. 49(2)
Diabetes-related microvascular complications include diabetic neuropathy (eg, diabetic symmetric polyneuropathy (DSPN), cardiac autonomic neuropathy, gastroparesis, enteropathy, erectile dysfunction, female sexual dysfunction, and hypoglycemia unawar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::626d12f14d3df7c553cd82597e3546d0
https://pubmed.ncbi.nlm.nih.gov/35595480
https://pubmed.ncbi.nlm.nih.gov/35595480
Publikováno v:
Diabetes, Obesity and Metabolism. 23:276-280
Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that has recently been shown to reduce the incidence of reported episodes of atrial fibrillation (AF)/atrial flutter in the DECLARE-TIMI 58 trial. This raises the question regarding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc47da804cd5da41a5116dbccc260e86
https://doi.org/10.1111/dom.14211
https://doi.org/10.1111/dom.14211
Autor:
Muna R. Mian, Stephanie O. Page, Doyle M. Cummings, Shivajirao P. Patil, Jarrod Uhrig, James R. Powell, Kerry Sewell, Basem M. Mishriky
Publikováno v:
The Journal of Clinical Pharmacology. 60:980-991
Our aim was to explore whether the baseline hemoglobin A1c or the dose of sodium glucose cotransporter-2 inhibitor (SGLT-2i) chosen better predicted the efficacy of SGLT-2i versus dipeptidyl peptidase-4 inhibitor (DPP-4i) in type 2 diabetes. We searc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f6b81df4d49dbd58de292dffc4e5534
https://doi.org/10.1002/jcph.1599
https://doi.org/10.1002/jcph.1599
Autor:
Jennifer A. Wittwer, Qiang Wu, Basem M. Mishriky, Doyle M. Cummings, Jennifer X. Chu, James R. Powell, Kerry Sewell
Publikováno v:
Diabetes, Obesity and Metabolism. 21:2274-2283
Aims While recent cardiovascular safety trials (CVST) concerning newer diabetes medications included mostly white participants, results are being generalized to all races in recent guidelines. This raises a controversial question regarding the approp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da6808bd4bde76bd28247783a2e5ddc
https://doi.org/10.1111/dom.13805
https://doi.org/10.1111/dom.13805
Publikováno v:
Diabetes & Metabolism. 45:102-109
Aims Our aim was to compare once-weekly semaglutide to incretin-based therapies – defined as either dipeptidyl peptidase-4 inhibitors (DPP-4i) or other glucagon-like peptide-1 receptor agonist (GLP-1RA) – in patients with type 2 diabetes. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c378daaecf3eebd16f67402b41558a
https://doi.org/10.1016/j.diabet.2018.09.002
https://doi.org/10.1016/j.diabet.2018.09.002